TENAYA THERAPEUTICS I

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

15 May 2025 20:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

13 May 2025 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

07 May 2025 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

24 Apr 2025 13:07:47 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

31 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

24 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

19 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

10 Mar 2025 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Pricing of Public Offering

03 Mar 2025 22:19:31 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Proposed Public Offering

03 Mar 2025 15:10:10 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

03 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

03 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

13 Jan 2025 08:16:36 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

17 Dec 2024 06:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

16 Dec 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

19 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

06 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM

17 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Tenaya Therapeutics to Participate in Upcoming Investment Conferences

03 Sep 2024 07:30:00 By Nasdaq GlobeNewswire